Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free OMDA Stock Alerts

Omada Health (OMDA) Financials

Omada Health logo
$16.56 -0.02 (-0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$16.57 +0.01 (+0.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Omada Health

Annual Income Statements for Omada Health

This table shows Omada Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -68 -47 -13
Consolidated Net Income / (Loss)		 -68 -47 -13
Net Income / (Loss) Continuing Operations		 -68 -47 -13
Total Pre-Tax Income 		-68 -47 -13
Total Operating Income		 -66 -44 -12
Total Gross Profit		 70 103 171
Total Revenue		 123 170 260
Operating Revenue		 123 170 260
Total Cost of Revenue		 53 67 89
Operating Cost of Revenue		 53 67 89
Total Operating Expenses		 136 147 183
Selling, General & Admin Expense		 36 43 52
Marketing Expense		 66 68 90
Research & Development Expense		 34 36 41
Total Other Income / (Expense), net		 -1.51 -3.48 -0.81
Interest Expense		 6.24 4.51 4.64
Interest & Investment Income		 5.78 0.81 5.31
Other Income / (Expense), net		 -1.05 0.22 -1.47
Income Tax Expense		 0.00 0.00 0.00
Basic Earnings per Share		 ($9.52) ($6.11) ($0.35)
Weighted Average Basic Shares Outstanding		 7.09M 7.72M 36.64M
Diluted Earnings per Share		 ($9.52) ($6.11) ($0.35)
Weighted Average Diluted Shares Outstanding		 7.09M 7.72M 36.64M
Weighted Average Basic & Diluted Shares Outstanding		 - - 58.93M

Quarterly Income Statements for Omada Health

This table shows Omada Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -9.23 -9.45 -5.31 -3.18 -2.97
Consolidated Net Income / (Loss)		 -11 -9.23 -9.45 -5.31 -3.18 -2.97
Net Income / (Loss) Continuing Operations		 -11 -9.23 -9.45 -5.31 -3.18 -2.97
Total Pre-Tax Income 		-11 -9.23 -9.45 -5.31 -3.18 -2.97
Total Operating Income		 -10 -8.52 -8.40 -4.34 -2.51 -4.78
Total Gross Profit		 25 29 32 40 45 49
Total Revenue		 41 46 55 61 68 78
Operating Revenue		 41 46 55 61 68 78
Total Cost of Revenue		 16 17 23 21 23 29
Operating Cost of Revenue		 16 17 23 21 23 29
Total Operating Expenses		 35 37 40 45 48 53
Selling, General & Admin Expense		 11 11 11 12 14 14
Marketing Expense		 15 18 20 22 23 27
Research & Development Expense		 8.99 8.85 8.81 10 10 13
Total Other Income / (Expense), net		 -0.66 -0.70 -1.05 -0.97 -0.67 1.81
Interest Expense		 1.13 1.15 1.07 1.09 2.46 0.02
Interest & Investment Income		 0.09 0.02 0.54 0.86 2.01 1.83
Other Income / (Expense), net		 0.39 0.43 -0.52 -0.74 -0.21 0.00
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($1.40) ($1.18) ($1.15) ($0.24) ($0.06) ($0.05)
Weighted Average Basic Shares Outstanding		 7.65M 7.79M 8.24M 21.97M 57.66M 58.92M
Diluted Earnings per Share		 ($1.40) ($1.18) ($1.15) ($0.24) ($0.06) ($0.05)
Weighted Average Diluted Shares Outstanding		 7.65M 7.79M 8.24M 21.97M 57.66M 58.92M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 57.57M 57.91M 59.45M

Annual Cash Flow Statements for Omada Health

This table details how cash moves in and out of Omada Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -52 -39 146
Net Cash From Operating Activities		 -50 -34 18
Net Cash From Continuing Operating Activities		 -50 -34 18
Net Income / (Loss) Continuing Operations		 -68 -47 -13
Consolidated Net Income / (Loss)		 -68 -47 -13
Depreciation Expense		 4.45 4.80 5.49
Amortization Expense		 2.22 3.03 3.62
Non-Cash Adjustments To Reconcile Net Income		 13 12 18
Changes in Operating Assets and Liabilities, net		 -1.50 -6.57 3.74
Net Cash From Investing Activities		 -2.92 -3.86 -5.83
Net Cash From Continuing Investing Activities		 -2.92 -3.86 -5.83
Purchase of Property, Plant & Equipment		 -2.92 -3.86 -5.83
Net Cash From Financing Activities		 0.18 -1.21 133
Net Cash From Continuing Financing Activities		 0.18 -1.21 133
Repayment of Debt		 -32 0.00 -32
Repurchase of Common Equity		 -0.11 -4.54 -4.28
Issuance of Debt		 31 0.00 0.00
Issuance of Common Equity		 0.00 0.00 161
Other Financing Activities, net		 1.76 3.33 9.37
Cash Interest Paid		 4.10 3.85 2.42

Quarterly Cash Flow Statements for Omada Health

This table details how cash moves in and out of Omada Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.44 -7.34 -17 -25 23 -10
Net Cash From Operating Activities		 1.06 -6.49 -16 10 21 -12
Net Cash From Continuing Operating Activities		 1.06 -6.49 -16 10 21 -12
Net Income / (Loss) Continuing Operations		 -9.23 -8.25 -9.45 -3.18 5.16 -2.97
Consolidated Net Income / (Loss)		 -9.23 -8.25 -9.45 -3.18 5.16 -2.97
Depreciation Expense		 1.23 1.28 1.33 1.36 1.45 1.51
Amortization Expense		 0.79 0.84 0.84 0.94 0.87 0.96
Non-Cash Adjustments To Reconcile Net Income		 2.56 3.74 4.19 6.50 3.87 5.02
Changes in Operating Assets and Liabilities, net		 5.70 -4.09 -13 4.51 10 -16
Net Cash From Investing Activities		 -1.07 -0.97 -1.25 -1.99 -1.35 -1.56
Net Cash From Continuing Investing Activities		 -1.07 -0.97 -1.25 -1.99 -1.35 -1.56
Purchase of Property, Plant & Equipment		 -1.07 -0.97 -1.25 -1.99 -1.35 -1.56
Net Cash From Financing Activities		 -0.42 0.11 0.37 -33 3.38 3.12
Net Cash From Continuing Financing Activities		 -0.42 0.11 0.37 -33 3.38 3.12
Repurchase of Common Equity		 -1.09 -1.17 -0.55 -2.36 0.00 0.00
Other Financing Activities, net		 0.67 1.28 0.92 2.09 3.38 3.12
Cash Interest Paid		 0.98 0.93 0.90 0.60 - 0.02

Annual Balance Sheets for Omada Health

This table presents Omada Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 151 305
Total Current Assets		 113 273
Cash & Equivalents		 76 222
Accounts Receivable		 23 35
Inventories, net		 3.30 4.49
Prepaid Expenses		 6.94 8.29
Other Current Assets		 3.02 3.54
Plant, Property, & Equipment, net		 5.63 7.94
Total Noncurrent Assets		 33 25
Goodwill		 13 13
Intangible Assets		 4.26 2.41
Other Noncurrent Operating Assets		 15 8.88
Total Liabilities & Shareholders' Equity		 151 305
Total Liabilities		 86 76
Total Current Liabilities		 54 76
Accounts Payable		 4.17 10
Accrued Expenses		 30 40
Current Deferred Revenue		 20 25
Total Noncurrent Liabilities		 32 0.00
Other Noncurrent Operating Liabilities		 2.54 0.00
Commitments & Contingencies		 0.00 0.00
Total Equity & Noncontrolling Interests		 -384 230
Total Preferred & Common Equity		 -384 230
Total Common Equity		 -384 230
Common Stock		 60 686
Retained Earnings		 -444 -457

Quarterly Balance Sheets for Omada Health

This table presents Omada Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2025 9/30/2025 3/31/2026
Total Assets		 303 287 303
Total Current Assets		 271 255 269
Cash & Equivalents		 223 199 212
Accounts Receivable		 33 41 40
Inventories, net		 3.47 3.15 3.83
Prepaid Expenses		 7.75 8.45 9.83
Other Current Assets		 3.45 3.23 4.02
Plant, Property, & Equipment, net		 6.48 7.54 8.46
Total Noncurrent Assets		 25 25 25
Goodwill		 13 13 13
Intangible Assets		 3.29 2.85 1.98
Other Noncurrent Operating Assets		 8.85 8.94 9.70
Total Liabilities & Shareholders' Equity		 303 287 303
Total Liabilities		 89 70 69
Total Current Liabilities		 58 70 69
Accounts Payable		 7.40 5.34 8.10
Accrued Expenses		 25 38 31
Current Deferred Revenue		 26 27 29
Total Noncurrent Liabilities		 31 0.00 0.00
Other Noncurrent Operating Liabilities		 0.80 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 214 217 234
Total Preferred & Common Equity		 214 217 234
Total Common Equity		 214 217 234
Common Stock		 673 679 694
Retained Earnings		 -459 -462 -460

Annual Metrics And Ratios for Omada Health

This table displays calculated financial ratios and metrics derived from Omada Health's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 57,908,047.00
DEI Adjusted Shares Outstanding		 0.00 0.00 57,908,047.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.22
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -46 -31 -8.38
Return On Investment Capital (ROIC_SIMPLE)		 - 8.62% -3.65%
Earnings before Interest and Taxes (EBIT)		 -67 -43 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -60 -36 -4.33
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -49 1.85
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 19 8.28
Increase / (Decrease) in Invested Capital		 0.00 19 -10
Book Value per Share		 $0.00 ($49.79) $3.97
Tangible Book Value per Share		 $0.00 ($52.05) $3.70
Total Capital		 0.00 94 230
Total Debt		 0.00 30 0.00
Total Long-Term Debt		 0.00 30 0.00
Net Debt		 0.00 -47 -222
Capital Expenditures (CapEx)		 2.92 3.86 5.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -17 -25
Debt-free Net Working Capital (DFNWC)		 0.00 59 197
Net Working Capital (NWC)		 0.00 59 197
Net Nonoperating Expense (NNE)		 21 17 4.40
Net Nonoperating Obligations (NNO)		 0.00 -46 -221
Total Depreciation and Amortization (D&A)		 6.66 7.84 9.12
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.35)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 36.64M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.35)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 36.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 58.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -46 -31 -8.38
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Omada Health

This table displays calculated financial ratios and metrics derived from Omada Health's official financial filings.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 - - 0.00 - - 58,925,439.00
DEI Adjusted Shares Outstanding		 - - 0.00 - - 58,925,439.00
DEI Earnings Per Adjusted Shares Outstanding		 - - 0.00 - - -0.05
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 48.92% 49.47% 42.00%
EBITDA Growth		 0.00% 0.00% 0.00% 47.33% 92.97% 65.65%
EBIT Growth		 0.00% 0.00% 0.00% 47.33% 66.34% 46.38%
NOPAT Growth		 0.00% 0.00% 0.00% 56.72% 70.52% 43.06%
Net Income Growth		 0.00% 0.00% 0.00% 50.33% 65.55% 68.56%
EPS Growth		 0.00% 0.00% 0.00% 82.86% 94.92% 95.65%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 859.56% 26.58%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 10.44% 0.00% 0.00% 10.85% 0.00%
EBITDA Q/Q Growth		 0.00% 37.00% 0.00% 0.00% 91.59% 0.00%
EBIT Q/Q Growth		 0.00% 16.06% 0.00% 0.00% 46.36% 0.00%
NOPAT Q/Q Growth		 0.00% 15.07% 0.00% 0.00% 42.15% 0.00%
Net Income Q/Q Growth		 0.00% 13.71% 0.00% 0.00% 40.16% 0.00%
EPS Q/Q Growth		 0.00% 15.71% 0.00% 0.00% 75.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -148.47% 0.00% 0.00% -155.35%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 14.94% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -11.01% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 60.26% 62.75% 58.04% 65.68% 66.25% 62.39%
EBITDA Margin		 -23.40% -13.35% -12.26% -8.28% -0.63% -2.97%
Operating Margin		 -24.35% -18.73% -15.28% -7.08% -3.69% -6.13%
EBIT Margin		 -23.40% -17.79% -16.22% -8.28% -4.01% -6.13%
Profit (Net Income) Margin		 -25.94% -20.27% -17.19% -8.65% -4.67% -3.81%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 110.86% 113.96% 105.97% 104.55% 116.62% 62.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -108.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -109.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 98.63%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% 0.00% -10.06%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -5.73%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -3.56%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% 0.00% -10.06%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.03 -5.97 -5.88 -3.04 -1.76 -3.35
NOPAT Margin		 -17.05% -13.11% -10.69% -4.95% -2.59% -4.29%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -2.35% -1.43% 0.36%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -1.25% -0.81% -1.43%
Cost of Revenue to Revenue		 39.74% 37.25% 41.96% 34.32% 33.75% 37.61%
SG&A Expenses to Revenue		 25.95% 23.42% 20.60% 20.06% 21.08% 17.92%
R&D to Revenue		 21.81% 19.44% 16.02% 16.33% 15.14% 16.27%
Operating Expenses to Revenue		 84.61% 81.48% 73.31% 72.75% 69.95% 68.51%
Earnings before Interest and Taxes (EBIT)		 -9.65 -8.10 -8.92 -5.08 -2.73 -4.78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.65 -6.08 -6.74 -5.08 -0.43 -2.32
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 1.88 5.87 3.16
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 2.03 6.33 3.38
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 2.61
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 9.93 57.49 23.66
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 1.87
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 5,288.97
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 23.47
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.14 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.14 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -0.90 -0.91 -0.90
Leverage Ratio		 0.00 0.00 0.00 1.41 1.32 1.29
Compound Leverage Factor		 0.00 0.00 0.00 1.48 1.54 0.80
Debt to Total Capital		 0.00% 0.00% 0.00% 12.27% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 12.27% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 87.73% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 6.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 0.00 0.00 4.68 3.64 3.92
Quick Ratio		 0.00 0.00 0.00 4.42 3.42 3.67
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -24 -20 -26
Operating Cash Flow to CapEx		 0.00% 98.88% -1,290.47% 0.00% 509.96% -760.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -22.01 -8.32 -1,427.76
Operating Cash Flow to Interest Expense		 0.00 0.92 -15.01 0.00 4.12 -657.44
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -0.01 -16.17 0.00 3.31 -743.94
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.94
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 7.09
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 24.94
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 33.51
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 11.80
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 51.52
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 14.63
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 30.94
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 35.21
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 0.00 0.00 21 19 22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 25.35
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 21 19 22
Enterprise Value (EV)		 0.00 0.00 0.00 209 1,076 529
Market Capitalization		 150 150 150 402 1,275 741
Book Value per Share		 $0.00 $0.00 $0.00 $9.75 $3.78 $3.97
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $9.00 $3.50 $3.71
Total Capital		 0.00 0.00 0.00 244 217 234
Total Debt		 0.00 0.00 0.00 30 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 30 0.00 0.00
Net Debt		 0.00 0.00 0.00 -193 -199 -212
Capital Expenditures (CapEx)		 0.00 1.07 1.25 0.00 1.99 1.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -10 -14 -11
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 213 185 201
Net Working Capital (NWC)		 0.00 0.00 0.00 213 185 201
Net Nonoperating Expense (NNE)		 3.67 3.26 3.57 2.27 1.42 -0.38
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -193 -199 -212
Total Depreciation and Amortization (D&A)		 0.00 2.02 2.18 0.00 2.30 2.47
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -3.89%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 70.86%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 70.86%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.24) ($0.06) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 21.97M 57.66M 58.92M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.24) ($0.06) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 21.97M 57.66M 58.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 57.57M 57.91M 59.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.03 -5.97 -5.88 -3.04 -1.76 -3.35
Normalized NOPAT Margin		 -17.05% -13.11% -10.69% -4.95% -2.59% -4.29%
Pre Tax Income Margin		 -25.94% -20.27% -17.19% -8.65% -4.67% -3.81%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -8.52 -7.06 -8.30 -4.64 -1.11 -265.61
NOPAT to Interest Expense		 -6.21 -5.20 -5.47 -2.78 -0.71 -185.93
EBIT Less CapEx to Interest Expense		 0.00 -7.99 -9.46 0.00 -1.91 -352.11
NOPAT Less CapEx to Interest Expense		 0.00 -6.13 -6.64 0.00 -1.52 -272.43
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -59.30%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Omada Health's recent quarterly statements, focusing on cash flow, profitability, liquidity, and leverage. The data show revenue growth in 2025, a quarterly profit in Q4 2025, and strong operating cash flow, but ongoing net losses and financing outflows in several periods.

  • Net cash from continuing operating activities rose to 21,379,000 in Q4 2025, signaling robust core operating cash flow.
  • Net income from continuing operations was 5,159,000 in Q4 2025, marking a quarterly profitability turnaround.
  • Revenue trend in 2025 shows top-line growth: Q3 2025 Operating Revenue was 68,030,000, up from 61,371,000 in Q2 2025.
  • Gross margin remained solid in Q3 2025, with Total Gross Profit of 45,071,000 on 68,030,000 in revenue (roughly 66% gross margin).
  • The balance sheet shows no long-term debt (Long-Term Debt = 0) and strong equity (Total Equity = 217,346,000), indicating a solid financial footing.
  • Cash and equivalents remained healthy at 198,627,000 in Q3 2025, providing substantial liquidity for operations and potential opportunities.
  • Capital expenditures were modest in Q4 2025 (Purchase of Property, Plant & Equipment = -1,346,000), indicating disciplined investment relative to cash flow.
  • Financing activities were a notable cash outflow in Q3 2025 (Net cash from financing activities around -32,665,000), signaling reliance on external funding that quarter.
  • Net income has been negative in most quarters of 2024–2025 (e.g., Q3 2025 continuing operations = -3,178,000), underscoring ongoing profitability volatility.
  • Cumulative losses are substantial, with retained earnings at -461,903,000 as of Q3 2025, weighing on equity quality despite positive quarterly results.
05/15/26 04:55 PM ETAI Generated. May Contain Errors.

Omada Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Omada Health's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Omada Health's net income appears to be on a downward trend, with a most recent value of -$12.78 million in 2025, falling from -$67.51 million in 2023. The previous period was -$47.14 million in 2024. See where experts think Omada Health is headed by visiting Omada Health's forecast page.

Omada Health's total operating income in 2025 was -$11.97 million, based on the following breakdown:
  • Total Gross Profit: $170.94 million
  • Total Operating Expenses: $182.91 million

Over the last 2 years, Omada Health's total revenue changed from $122.78 million in 2023 to $260.21 million in 2025, a change of 111.9%.

Omada Health's total liabilities were at $75.73 million at the end of 2025, a 12.2% decrease from 2024, and a 12.2% decrease since 2024.

In the past 1 years, Omada Health's cash and equivalents has ranged from $76.39 million in 2024 to $222.04 million in 2025, and is currently $222.04 million as of their latest financial filing in 2025.

Over the last 2 years, Omada Health's book value per share changed from 0.00 in 2023 to 3.97 in 2025, a change of 396.6%.


Related Companies

Financial statements for NASDAQ:OMDA last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel